Effect size analyses of souvenaid in patients with Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 55, Issue 3, 2017, Pages 1131-1139

  Cummings, Jeffrey ^a   Scheltens, Philip ^b   Mckeith, Ian ^c   Blesa, Rafael ^d   Harrison, John E ^b,e   Bertolucci, Paulo H F ^f   Rockwood, Kenneth ^g,h,i   Wilkinson, David ^j   Wijker, Wouter ^k   Bennett, David A ^l   Shah, Raj C ^l  

^a CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e METIS COGNITION LTD   (United Kingdom)

^f FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^g DALHOUSIE UNIVERSITY   (Canada)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

ⁱ DGI Clinical Inc   (Canada)

^j UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^k Auxiliis BV   (Netherlands)

^l RUSH UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Alzheimer's disease; effect size; number needed to treat; Souvenaid

Indexed keywords

ALPHA TOCOPHEROL PLUS ASCORBIC ACID PLUS CHOLINE PLUS CYANOCOBALAMIN PLUS DOCOSAHEXAENOIC ACID PLUS EICOSAPENTAENOIC ACID PLUS FOLIC ACID PLUS PHOSPHOLIPID PLUS PYRIDOXINE PLUS SELENIUM PLUS URIDINE MONOPHOSPHATE; NOOTROPIC AGENT; UNCLASSIFIED DRUG; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; NEUROLEPTIC AGENT; SELENIUM; VITAMIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; COGNITION; DAILY LIFE ACTIVITY; DIETARY SUPPLEMENT; DRUG SAFETY; EFFECT SIZE; EXECUTIVE FUNCTION; FEMALE; FUNCTIONAL STATUS; GASTROINTESTINAL DISEASE; HUMAN; INTENTION TO TREAT ANALYSIS; MALE; MEMORY; NEUROPSYCHOLOGICAL TEST; NUMBERS NEEDED TO TREAT; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECALL; RESPIRATORY TRACT DISEASE; WECHSLER MEMORY SCALE; AGED; CONTROLLED STUDY; DIET THERAPY; FOLLOW UP; FUNCTIONAL FOOD; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FEMALE; FOLLOW-UP STUDIES; FUNCTIONAL FOOD; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; SELENIUM; TREATMENT OUTCOME; VITAMINS;

EID: 85005943178     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160745     Document Type: Article

References (28)

1. Scheff SW, Price DA, Schmitt FA, Scheff MA, Mufson EJ. (2011) Synaptic loss in the inferior temporal gyrus in mild cognitive impairment and Alzheimer?s disease. J Alzheimers Dis 24, 547-557.
2. Raskin J, Cummings J, Hardy J, Schuh K, Dean RA. (2015) Neurobiology of Alzheimer?s Disease: Integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions. Curr Alzheimer Res 12, 712-722.
3. Wurtman RJ, Cansev M, Sakamoto T, Ulus IH. (2009) Use of phosphatide precursors to promote synaptogenesis. Annu Rev Nutr 29, 59-87.
4. Lopes da Silva S, Vellas B, Elemans S, Luchsinger J, Kamphuis P, Yaffe K, Sijben J, Groenendijk M, Stijnen T. (2014) Plasma nutrient status of patients with Alzheimer?s disease: Systematic review and meta-Analysis. Alzheimers Dement 10, 485-502.
5. Gustafson DR, Clare Morris M, Scarmeas N, Shah RC, Sijben J, Yaffe K, Zhu X. (2015) New perspectives on Alzheimer?s disease and nutrition. J Alzheimers Dis 46, 1111-1127.
6. Mi W, van Wijk N, Cansev M, Sijben JW, Kamphuis PJ. (2013) Nutritional approaches in the risk reduction and management of Alzheimer?s disease. Nutrition 29, 1080-1089.
7. van Wijk N, Broersen LM, de Wilde MC, Hageman RJ, Groenendijk M, Sijben JW, Kamphuis PJ. (2014) Targeting synaptic dysfunction in Alzheimer?s disease by administering a specific nutrient combination. J Alzheimers Dis 38, 459-479.
8. Cansev M, van Wijk N, Turkyilmaz M, Orhan F, Sijben JW, Broersen LM. (2015) Specific multi-nutrient enriched diet enhances hippocampal cholinergic transmission in aged rats. Neurobiol Aging 36, 344-351.
9. Zerbi V, Jansen D, Wiesmann M, Fang X, Broersen LM, Veltien A, Heerschap A, Kiliaan AJ. (2014) Multinutrient diets improve cerebral perfusion and neuroprotection in a murine model of Alzheimer?s disease. Neurobiol Aging 35, 600-613.
10. de Wilde MC, Penke B, van der Beek EM, Kuipers AA, Kamphuis PJ, Broersen LM. (2011) Neuroprotective effects of a specific multi-nutrient intervention against A-42-induced toxicity in rats. J Alzheimers Dis 27, 327-339.
11. Broersen LM, Kuipers AA, Balvers M, vanWijk N, Savelkoul PJ, de Wilde MC, van der Beek EM, Sijben JW, Hageman RJ, Kamphuis PJ, Kiliaan AJ. (2013) A specific multi-nutrient diet reduces Alzheimer-like pathology in young adult A-PPswe/PS1dE9 mice. J Alzheimers Dis 33, 177-190.
12. Jansen D, Zerbi V, Arnoldussen IA, Wiesmann M, Rijpma A, Fang XT, Dederen PJ, Mutsaers MP, Broersen LM, Lütjohann D, Miller M, Joosten LA, Heerschap A, Kiliaan AJ. (2013) Effects of specific multi-nutrient enriched diets on cerebral metabolism, cognition and neuropathology in A-PPswe-PS1dE9 mice. PLoS One 8, e75393.
13. Scheltens P, Kamphuis PJ, Verhey FR, Olde Rikkert MG, Wurtman RJ, Wilkinson D, Twisk JW, Kurz A. (2010) Efficacy of a medical food in mild Alzheimer?s disease: A randomized, controlled trial. Alzheimers Dement 6, 1-10 e1.
14. Scheltens P, Twisk JW, Blesa R, Scarpini E, von Arnim CA, Bongers A, Harrison J, Swinkels SH, Stam CJ, de Waal H, Wurtman RJ, Wieggers RL, Vellas B, Kamphuis PJ. (2012) Efficacy of Souvenaid in mild Alzheimer?s disease: Results from a randomized, controlled trial. J Alzheimers Dis 31, 225-236.
15. Shah RC, Kamphuis PJ, Leurgans S, Swinkels SH, Sadowsky CH, Bongers A, Rappaport SA, Quinn JF, Wieggers RL, Scheltens P, Bennett DA. (2013) The S-Connect study: Results from a randomized, controlled trial of Souvenaid in mild-To-moderate Alzheimer?s disease. Alzheimers Res Ther 5, 59.
16. Olde Rikkert MG, Verhey FR, Blesa R, von Arnim CA, Bongers A, Harrison J, Sijben J, Scarpini E, Vandewoude MF, Vellas B, Witkamp R, Kamphuis PJ, Scheltens P. (2015) Tolerability and safety of Souvenaid in patients with mild Alzheimer?s disease: Results of multi-center, 24-week, open-label extension study. J Alzheimers Dis 44, 471-480.
17. Rockwood K. (2004) Size of the treatment effect on cognition of cholinesterase inhibitors in Alzheimer?s disease. J Neurol Neurosurg Psychiatry 75, 677-685.
18. Cohen J. (1988) The t test for means. In Statistical Power Analysis for the Behavioral Sciences, Second Edition, Cohen JL. Lawrence Erlbaum Associates, Mahwah, NJ, pp. 19-74.
19. Cramér H. (1946) Mathematical Methods of Statistics. Princeton University Press.
20. Furukawa TA, Leucht S. (2011) How to obtain NNT from Cohen?s d: Comparison of two methods. PLoS One 6, e19070.
21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. (1984) Clinical diagnosis of Alzheimer?s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer?s Disease. Neurology 34, 939-944.
22. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM. (2005) Clinical effects of Abeta immunization. (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562.
23. Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. (2007) A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 64, 1323-1329.
24. Lanct?ot KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, Einarson TR. (2003) Efficacy and safety of cholinesterase inhibitors in Alzheimer?s disease: A metaanalysis. CMAJ 169, 557-564.
25. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. (2008) Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer?s disease: A systematic review and metaanalysis. Clin Interv Aging 3, 211-225.
26. Peters KR. (2013) Utility of an effect size analysis for communicating treatment effectiveness: A case study of cholinesterase inhibitors for Alzheimer?s disease. J Am Geriatr Soc 61, 1170-1174.
27. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M. (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Ann Intern Med 148, 379-397.
28. Rijpma A, Meulenbroek O, van Hees AM, Sijben JW, Vellas B, Shah RC, Bennett DA, Scheltens P, Olde Rikkert MG. (2015) Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-To-moderate Alzheimer?s disease. Alzheimers Res Ther 7, 51.